By Fineline Cube Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED Co., Ltd. (TYO: 4263) regarding a digital therapeutic for insomnia. The two companies originally entered into a commercialization agreement for the therapy in 2021, centered on SUSMED’s Med CBT‑i application, which delivers cognitive behavioral therapy for insomnia (CBT‑I) to patients.
Deal Milestone
| Element | Detail |
|---|---|
| Parties | Shionogi & Co., Ltd. (TYO: 4507) and SUSMED Co., Ltd. (TYO: 4263) |
| Event | Termination of collaboration agreement |
| Asset | Med CBT‑i, a digital therapeutic for insomnia |
| Original Agreement | Commercialization agreement entered in 2021 |
| Announcement Date | 26 Aug 2026 |
| Next Steps | Not specified in the announcement |
Partnership Timeline & Background
- 2021: Shionogi and SUSMED entered a commercialization agreement covering SUSMED’s digital insomnia therapy.
- Aug 2023: SUSMED’s Med CBT‑i insomnia application was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) to deliver cognitive behavioral therapy for insomnia (CBT‑I) to patients.
- Aug 2026: Shionogi announced the termination of the collaboration.
Product Profile & Mechanism of Action
- Product: Med CBT‑i, a prescription digital therapeutic application
- Indication: Insomnia
- Modality: Software‑delivered cognitive behavioral therapy for insomnia (CBT‑I), the first‑line, non‑pharmacological standard of care for chronic insomnia
- Regulatory Status: Approved by Japan’s MHLW in August 2023
- Treatment Regimen: Patients follow treatments prompted by the product over a 9‑week period
- Therapeutic Effect: Achieves therapeutic effects for insomnia symptoms through structured, app‑guided CBT‑I
Market Impact & Outlook
- Strategic Reassessment: The termination signals Shionogi’s withdrawal from the commercialization of digital therapeutics for insomnia, refocusing its portfolio priorities.
- Japan’s DTx Landscape: The split tests the commercial viability of prescription digital therapeutics in Japan, where reimbursement and adoption models remain nascent despite the pioneering MHLW approval of Med CBT‑i in 2023.
- Impact on SUSMED: SUSMED will need to pursue commercialization of Med CBT‑i independently or with a new partner, making upcoming adoption and revenue metrics a key watch item for investors in TYO: 4263.
- Watch Items: Any further commentary from either company on the operational and financial implications of the termination, and the future strategic path for the Med CBT‑i franchise.
Forward‑Looking Statements – This brief is for informational purposes only and does not constitute investment, medical, or regulatory advice. Statements regarding future commercialization and market development are forward‑looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements from Shionogi and SUSMED for authoritative details.-Fineline Info & Tech